Neutrophil CD10 and CD16 as markers of generalized infection development in newborns

Abstract

BACKGROUND: Neonatal sepsis remains a critical concern. Thus, predictors of infection development and generalization should be determined.

AIM: This study aimed to determine novel neutrophil surface biomarkers for early prediction of the infections in newborns.

MATERIALS AND METHODS: This observational, single-center, prospective, selective, uncontrolled, unblinded experimental study included 261 newborns, with a mean postconceptual age of 38.7 (38.4–39.0) weeks and a mean gestation age of 38.0 (37.7–38.2) weeks. Blood samples were collected into vacutainers on hospitalization day 1. Patients were enrolled between April 2022 and December 2023. The primary endpoints were length of stay in the ICU and total length of hospitalization in patients with normal and decreased values of CD16 and CD10 neutrophils and HLA-DR monocytes. The expression of CD16 on CD62L^high neutrophils, total neutrophil CD10, and monocyte HLA-DR were evaluated by flow cytometry.

RESULTS: We assessed infants in the “control” (n = 96), “localized infection” (n = 95), and “generalized infection” (n = 70) subgroups. In all patients, a decrease in CD16 was associated with an increase in the median ICU stay from 4 to 8 days (p = 9.33 × 10^–8) and total stay from 14 to 22 days (p = 1.58 × 10^–7). A decrease in CD10 was associated with an increase in median ICU stay from 4 to 8 days (p = 3.01 × 10^–6) and in the total stay from 14 to 19 days (p = 2.78 × 10^–5). A decrease in monocytic HLA-DR was associated with a longer ICU and total hospital stay: 4 vs 8 days (p = 7.16 × 10^–5) and 14 vs 21 days (p = 4.03 × 10^–5), respectively. The median ICU stay in patients with a decrease in CD16 but normal CD10 was 4 days, whereas a decrease in both indicators was associated with prolonged hospital stay to 11 days (p = 2.13 × 10^–5). The median hospital stay in patients with decreased CD16 but normal CD10 was 16 days, whereas the drop of both markers was related with increase of hospitalization stay to 23 days (p = 3.36 × 10^–6). In the “localized infection” subgroup, low CD16 was associated with an increased median ICU stay from 4 to 6 days (p = 0.010) and the median hospital stay from 13 to 19 days (p = 4.14 × 10^–4). In the “generalized infection” subgroup, decreased CD10 was related with prolongation of the median ICU stay from 7 to 11 days (p = 0.011) and the median total duration of hospitalization from 19 to 27 days (p = 0.037).

CONCLUSIONS: A decrease in CD10 and CD16 on the neutrophils at the start of clinical is an unfavorable prognostic factor of infectious and septic complications in newborns.

Keywords

CD10 / CD16 / CD62L / HLA-DR / neutrophils / monocytes / neonatal sepsis / children

References

[1] Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi: 10.1001/jama.2016.0287

[2] Singer M., Deutschman C.S., Seymour C.W., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) // JAMA. 2016. Vol. 315, N 8. P. 801–810. doi: 10.1001/jama.2016.0287

[3] Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770–1780. doi: 10.1016/S0140-6736(17)31002-4

[4] Shane A.L., Sánchez P.J., Stoll B.J. Neonatal sepsis // Lancet. 2017. Vol. 390, N 10104. P. 1770–1780. doi: 10.1016/S0140-6736(17)31002-4

[5] Kalashnikova AA, Voroshilova TM. Evaluation of CD64 expression by blood neutrophils in the diagnosis of bacterial infections and sepsis. Handbook of the head of CDL. 2016;5:44–54. EDN WCKTVF (In Russ.)

[6] Калашникова А.А., Ворошилова Т.М. Оценка экспрессии CD64 нейтрофилами крови в диагностике бактериальных инфекций и сепсиса // Справочник заведующего КДЛ. 2016. № 5. С. 44–54. EDN: WCKTVF

[7] Eichberger J, Resch E, Resch B. Diagnosis of neonatal sepsis: the role of inflammatory markers. Front Pediatr. 2022;10:840288. doi: 10.3389/fped.2022.840288

[8] Eichberger J., Resch E., Resch B. Diagnosis of neonatal sepsis: the role of inflammatory markers // Front Pediatr. 2022. Vol. 10. P. 840288. doi: 10.3389/fped.2022.840288

[9] Muhin VE, Pankrat’eva LL, Yarcev MN, Volodin NN. Developmental adaptations of neonatal neutrophils (review). Russian Journal of Allergy. 2021;18(2):55–65. EDN: DQEFLW. doi: 10.36691/RJA1438

[10] Мухин В.Е., Панкратьева Л.Л., Ярцев М.Н., Володин Н.Н. Особенности онтогенетической адаптации нейтрофилов новорожденного (обзор литературы) // Российский аллергологический журнал. 2021. Т. 18, № 2. С. 55–65. EDN: DQEFLW doi: 10.36691/RJA1438

[11] Patent RU No. 2374646/ 27.11.09. Byul. No. 33. Dudareva MV, Lelik MP, Puhtinskaya MG. Method of early diagnosis of neonatal sepsis development in newborns with respiratory distress syndrome and hypoxic CNS damage. (In Russ.) [cited 2024 Aug 14]. Available from: https://patents.google.com/patent/RU2374646C1/ru

[12] Патент РФ на изобретение № 2374646/ 27.11.09. Бюл. №33. Дударева М.В., Лелик М.П., Пухтинская М.Г. Способ ранней диагностики развития неонатального сепсиса у новорожденных с синдромом дыхательных расстройств и гипоксическим поражением ЦНС. Режим доступа: https://patents.google.com/patent/RU2374646C1/ru Дата обращения: 14.08.2024.

[13] Obraztsov IV, Obraztsova AA, Voronina OV, et al. Prediction of infectious and septic processes in newborns using the study of CD10 and CD16 neutrophils [proceedings] In: Collection of studies of young scientists competition in the framework of the conference “Current issues and innovative technologies in anesthesiology and resuscitation” (2024 April 5–6, Saint Petersburg). 2024. P. 10–14.

[14] Образцов И.В., Образцова А.А., Воронина О.В., и др. Прогнозирование инфекционно-септических процессов у новорожденных при помощи исследования CD10 и CD16 нейтрофилов [тезисы]. В кн.: Сборник работ конкурса молодых ученых научно-образовательной конференции «Актуальные вопросы и инновационные технологии в анестезиологии и реаниматологии» (5–6 апреля 2024 г., Санкт-Петербург). 2024. С. 10–14

[15] Elghetany MT. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis. 2002;28(2):260–274. doi: 10.1006/bcmd.2002.0513

[16] Elghetany M.T. Surface antigen changes during normal neutrophilic development: a critical review // Blood Cells Mol Dis. 2002. Vol. 28, N 2. P. 260–274. doi: 10.1006/bcmd.2002.0513

[17] Marini O, Costa S, Bevilacqua D, et al. Mature CD10+ and immature CD10– neutrophils present in G-CSF-treated donors display opposite effects on T cells [published correction appears in Blood. 2017;129(24):3271. doi: 10.1182/blood-2017-05-783423]. Blood. 2017;129(10):1343–1356. doi: 10.1182/blood-2016-04-713206

[18] Marini O., Costa S., Bevilacqua D., et al. Mature CD10+ and immature CD10– neutrophils present in G-CSF-treated donors display opposite effects on T cells [published correction appears in Blood. 2017. Vol. 129, N 24. P. 3271. doi: 10.1182/blood-2017-05-783423] // Blood. 2017. Vol. 129, N 10. P. 1343–1356. doi: 10.1182/blood-2016-04-713206

[19] Meng Y, Ye F, Nie P, et al. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. J Hepatol. 2023;79(6):1435–1449. doi: 10.1016/j.jhep.2023.08.024

[20] Meng Y., Ye F., Nie P., et al. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells // J Hepatol. 2023. Vol. 79, N 6. P. 1435–1449. doi: 10.1016/j.jhep.2023.08.024

[21] Kaneko T, Stearns-Kurosawa DJ, Taylor FJr, et al. Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide. Shock. 2003;20(2):130–137. doi: 10.1097/01.shk.0000068326.68761.34

[22] Kaneko T., Stearns-Kurosawa D.J., Taylor F.Jr., et al. Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide // Shock. 2003. Vol. 20, N 2. P. 130–137. doi: 10.1097/01.shk.0000068326.68761.34

[23] Liu M, Wang G, Wang L, et al. Immunoregulatory functions of mature CD10+ and immature CD10– neutrophils in sepsis patients. Front Med (Lausanne). 2023;9:1100756. doi: 10.3389/fmed.2022.1100756

[24] Liu M., Wang G., Wang L., et al. Immunoregulatory functions of mature CD10+ and immature CD10– neutrophils in sepsis patients // Front Med (Lausanne). 2023. Vol. 9. P. 1100756. doi: 10.3389/fmed.2022.1100756

[25] Liu J, Shi H, Yu J, Xiong J. CD10 is a good biomarker to predict bacterial infection in sepsis-suspected patients. Acta Med Mediterr. 2019;35:2851. doi: 10.19193/0393-6384_2019_5_448

[26] Liu J., Shi H., Yu J., Xiong J. CD10 is a good biomarker to predict bacterial infection in sepsis-suspected patients // Acta Med Mediterr. 2019. Vol. 35. P. 2851. doi: 10.19193/0393-6384_2019_5_448

[27] Muhin VE, Praulova DA, Pankrat’eva LL. Expression of Fc-gamma receptors of neutrophils in premature infants of different gestational ages. Current Pediatrics. 2016;15(3):273–278. EDN: WHHHTH doi: 10.15690/vsp.v15i3.1565

[28] Мухин В.Е., Праулова Д.А., Панкратьева Л.Л., и др. Экспрессия Fc-gamma рецепторов нейтрофилов у недоношенных детей различного гестационного возраста // Вопросы современной педиатрии. 2016. Т. 15, № 3. С. 273–278. EDN: WHHHTH doi: 10.15690/vsp.v15i3.1565

[29] Lakschevitz FS, Hassanpour S, Rubin A, et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342(2):200–209. doi: 10.1016/j.yexcr.2016.03.007

[30] Lakschevitz F.S., Hassanpour S., Rubin A., et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry // Exp Cell Res. 2016. Vol. 342, N 2. P. 200–209. doi: 10.1016/j.yexcr.2016.03.007

[31] Medara N, Lenzo JC, Walsh KA, et al. Peripheral neutrophil phenotypes during management of periodontitis. J Periodontal Res. 2021;56(1):58–68. doi: 10.1111/jre.12793

[32] Medara N., Lenzo J.C., Walsh K.A., et al. Peripheral neutrophil phenotypes during management of periodontitis // J Periodontal Res. 2021. Vol. 56, N 1. P. 58–68. doi: 10.1111/jre.12793

[33] Fraser JA, Kemp S, Young L, et al. Silver nanoparticles promote the emergence of heterogeneic human neutrophil sub-populations. Sci Rep. 2018;8(1):7506. doi: 10.1038/s41598-018-25854-2

[34] Fraser J.A., Kemp S., Young L., et al. Silver nanoparticles promote the emergence of heterogeneic human neutrophil sub-populations // Sci Rep. 2018. Vol. 8, N 1. P. 7506. doi: 10.1038/s41598-018-25854-2

[35] Zhang J, Gao C, Zhu Z, et al. New findings on CD16brightCD62Ldim neutrophil subtypes in sepsis-associated ARDS: an observational clinical study. Front Immunol. 2024;15:1331050. doi: 10.3389/fimmu.2024.1331050

[36] Zhang J., Gao C., Zhu Z., et al. New findings on CD16brightCD62Ldim neutrophil subtypes in sepsis-associated ARDS: an observational clinical study // Front Immunol. 2024. Vol. 15. P. 1331050. doi: 10.3389/fimmu.2024.1331050

[37] Dransfield I, Buckle AM, Savill JS, et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol. 1994;153(3):1254–1263.

[38] Dransfield I., Buckle A.M., Savill J.S., et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression// J Immunol. 1994. Vol. 153, N 3. P. 1254–1263.

[39] Lu Y, Huang Y, Huang L, et al. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients. BMC Immunol. 2020;21(1):46. doi: 10.1186/s12865-020-00375-8

[40] Lu Y., Huang Y., Huang L., et al. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients // BMC Immunol. 2020. Vol. 21, N 1. P. 46. doi: 10.1186/s12865-020-00375-8

[41] Butcher SK, Chahal H, Nayak L, et al. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. J Leukoc Biol. 2001;70(6):881–886.

[42] Butcher S.K., Chahal H., Nayak L., et al. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans // J Leukoc Biol. 2001. Vol. 70, N 6. P. 881–886.

Funding

Автономная некоммерческая организация «Московский центр инновационных технологий в здравоохранении»Autonomous non-profit organization "Moscow Center for Innovative Technologies in Healthcare"(1712-3/22)

RIGHTS & PERMISSIONS

Eco-Vector